LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ)
$0.6654 0.0154 (2.3692%)
Analysed LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) News Sources
Lexaria to Begin New Human Clinical Study in GLP-1
01-04-2026
yahoo.com
Lexaria Applauds Eli Lilly's Foundayo(TM) Drug Approval
07-04-2026
yahoo.com
Lexaria Bioscience (NASDAQ:LEXX) Will Have To Spend Its Cash Wisely
15-04-2026
yahoo.com
Lexaria's New Animal Study Aims to Expand Valuable Intellectual Property
15-04-2026
yahoo.com
Lexaria Expects Oral GLP-1 Pills to Generate Billions in New Industry Sales
21-04-2026
yahoo.com
Lexaria Launches New Study to Examine Next-Generation GLP-1 Drugs
23-04-2026
yahoo.com
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended
29-04-2026
yahoo.com
Lexaria Bioscience Launches Ongoing Investor Video Series to Expand Shareholder Communications
01-05-2026
yahoo.com
Lexaria Updates Progress on Human Study #7
05-05-2026
yahoo.com
Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #7
19-05-2026
yahoo.com
What is the current price of LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ)?
The current price of LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) is $0.6654.
LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) absolute price change since previous trading day?
The absolute price change of LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) since the previous trading day is $0.0154.
LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) percentage price change since previous trading day?
The percentage price change of LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) since the previous trading day is 2.3692%.
What is the most recent average sentiment score for LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ)?
The most recent average sentiment score for LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) is 73 out of 100.
What is the most recent average sentiment for LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ)?
The most recent sentiment for LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ) is .
SEC-8K** Filing Available For LEXARIA BIOSCIENCE CORP (LEXX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.